Todas las noticias

• Revenue up 4% • Improved results • Stronger growth potential

In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders deferred from the first half of the year. With revenue of €3.8 million, up 34% compared with Q4 2024 (€2.8 million), Spineway recorded a particularly dynamic fourth quarter.

Spineway, a specialist in innovative implants for the treatment of spine disorders, announces the commercial launch of its VEOS and Twin Peaks ranges in Colombia.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that it has conducted several training sessions for surgeons in Europe and Asia, confirming its commitment to helping practitioners master its innovative solutions.

Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboration avec Evolution Surgical la transition auprès des clients.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, is announcing its participation in the EUROSPINE 2025 congress, to be held from October 22 to 24, 2025, in Copenhagen, Denmark.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, benefited, in line with its expectations, from a deferral of orders from major accounts to the third quarter of 2025 and generated revenue of €3.0 million over the period, up from €2.6 million for the same period last year (+18%).

The Spineway Group, a specialist in innovative implants and instruments for the treatment of severe spine disorders, is celebrating its 20th anniversary this year. Throughout its history, the company has demonstrated an unwavering commitment to innovation and offering surgeons more effective technologies to improve quality of life for patients in France and around the world.

Continued improvement in results and financial position / Full-year 2025 growth target confirmed